ライフサイエンスコーパス: protective antigen

1 or with an isogenic mutant deficient for the protective antigen.

2 s a virulence factor, YopE can function as a protective antigen.

3 he phenylalanine clamp identified in anthrax protective antigen.

4 at lipopolysaccharide (LPS) is the major OMV protective antigen.

5 o predict the likelihood that a protein is a protective antigen.

6 a major surface antigen of sporozoites, is a protective antigen.

7 s a membrane-anchored glycoprotein and major protective antigen.

8 ce in the lungs and that rPsrP(SRR1-BR) is a protective antigen.

9 GAS esterase and determining whether it is a protective antigen.

10 ed in sporozoites and EEFs, CS is a dominant protective antigen.

11 esses lethal factor and the receptor-binding protective antigen.

12 sed by furin-dependent processing of anthrax protective antigen.

13 lethal toxin, a mixture of lethal factor and protective antigen.

14 es and a poor understanding of its role as a protective antigen.

15 in the endosomal membrane formed by anthrax protective antigen.

16 is considered both a virulence factor and a protective antigen.

17 e nucleus for efficient synthesis of encoded protective antigens.

18 ) glycoproteins are major neutralization and protective antigens.

19 flagellar proteins are virulence factors and protective antigens.

20 sis system that curates, stores and analyzes protective antigens.

21 ed methods will fail to discover truly novel protective antigens.

22 al polysaccharides are often immunodominant, protective antigens.

23 d the screening and characterization of tick protective antigens.

24 dence that fimbrial tip adhesins function as protective antigens.

25 on empirical evidence that these function as protective antigens.

26 e lack of broad-spectrum fungal vaccines and protective antigens.

27 xin (LT) are important virulence factors and protective antigens.

28 t are attenuated yet capable of synthesizing protective antigens.

29 Ad.D4 elicited antibodies to protective antigen 14 days after a single intramuscular

30 ion channel formed by the Bacillus anthracis protective antigen 63 (PA(63)).

31 ctor (LF) and/or Oedema Factor (EF) bound to Protective Antigen 63 (PA63) which functions as both the

32 1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin.

33 ne expressing domain 4 of Bacillus anthracis protective antigen, Ad.D4.

34 protein (F1-V) has shown great promise as a protective antigen against aerosol challenge with Y. pes

35 opE(Nt138)-LcrV), to Swiss Webster mice as a protective antigen against infections by yersiniae.

36 n and thus reveal a paradigm for identifying protective antigens against S. aureus.

37 U2/FP59, composed of the urokinase-activated protective antigen and a fusion protein of Pseudomonas e

38 been well characterized as a surface-exposed protective antigen and a virulence factor of S. pneumoni

39 llus anthracis edema toxin (ET), composed of protective antigen and an adenylate cyclase edema factor

40 emonstrated that detection of the biomarkers protective antigen and capsule correlated with bacterial

41 escence (ECL) immunoassay for the biomarkers protective antigen and capsule.

42 rrA bound to the promoters of genes for both protective antigen and cytochrome aa3, demonstrating tha

43 aracterized the levels of antibodies against protective antigen and found that over half of anthrax v

44 ered recently in Ixodes scapularis as a tick protective antigen and has a role in tick blood digestio

45 vaginal IgA titers against the heterologous protective antigen and higher levels of antigen-specific

46 s to two complex antigens-Bacillus anthracis protective antigen and influenza hemagglutinin-in which

47 ve developed a multiplex biomarker assay for protective antigen and lethal factor of the Bacillus ant

48 These data demonstrate that CFP-10 is a protective antigen and that CFP-10(32-39)-specific CD8+

49 ecific targets, including Bacillus anthracis protective antigen and the enzyme cofactor biotin.

50 ndopeptidase essential for the activation of protective antigen and the formation of anthrax lethal t

51 hracis, comprises a receptor-binding moiety, protective antigen and the lethal factor (LF) protease(1

52 he increasing structural characterization of protective antigens and epitopes provide the molecular a

53 d T cells that recognize components of these protective antigens and mediate protection.

54 limited by incomplete information regarding protective antigens and the requirement for multiple boo

55 B-type toxins, edema toxin (edema factor and protective antigen) and lethal toxin (lethal factor and

56 antigen) and lethal toxin (lethal factor and protective antigen), and a poly-d-glutamic acid capsule.

57 the genes for anthrax toxins (lethal factor, protective antigen, and edema factor) where expressed 4-

58 Anthrax lethal factor (LF), anti-protective antigen (anti-PA) immunoglobulin G (IgG), and

59 ings are consistent with the ability of anti-protective antigen antibodies to prevent anthrax and sug

60 erage on the liposomes; and immobilized anti-protective antigen antibody concentration.

61 ut subunit vaccines containing broadly cross-protective antigens are desirable.

62 ether, these data demonstrate that different protective antigens are required based on the route of v

63 Protective antigens are specifically targeted by the acq

64 CXO1 encodes pagA1, the homologue of anthrax protective antigen, as well as hasACB, providing for hya

65 vitro and in vivo; it targets the N-terminal protective antigen binding domain.

66 and IgG2b variants of the Bacillus anthracis protective antigen-binding IgG1 monoclonal antibody (mAb

67 vised ML classification to predict bacterial protective antigens (BPAgs).

68 ial cell surface and is a well-characterized protective antigen but is not essential for virulence.

69 proteins are independent neutralization and protective antigens, but the contribution by F is greate

70 -reactive VHHs block binding of EF/LF to the protective antigen C-terminal binding interface, prevent

71 mposed of phenylalanine (Phe)427 residues of protective antigen catalyses protein translocation via a

72 The protective antigen component of Bacillus anthracis toxin

73 sed lethal toxin receptor protein, bound the protective antigen component of lethal toxin, and were s

74 ed on VHHs with in vivo activity against the protective antigen component of the anthrax toxins.

75 tibody fragments engineered to recognize the protective antigen component of the B. anthracis exotoxi

76 abbits and monkeys, the time to detection of protective antigen correlated with the time to bacteremi

77 d GPI-linked parasite protein, Cysteine-rich protective antigen (CyRPA) as an interacting partner of

78 H5 interacting protein (RIPR), cysteine-rich protective antigen (CyRPA), apical membrane antigen 1 (A

79 These results provide in vivo evidence of protective antigen-dependent CD8+ T-cell proliferation,

80 We investigated whether protective antigen-directed monoclonal antibody (PA-mAb)

81 increased mortality (0.8 +/- 0.3, p = .006), protective antigen-directed monoclonal antibody alone re

82 normal saline for 6 hrs or combining it with protective antigen-directed monoclonal antibody followin

83 reatment either alone or in combination with protective antigen-directed monoclonal antibody in a let

84 t significant for all) or when combined with protective antigen-directed monoclonal antibody, so this

85 For example, Protegen stores over 800 protective antigens experimentally proven valid for vacc

86 Using 5 Staphylococcus aureus protective antigens expressed in Escherichia coli as fus

87 only 89 and 87% amino acid identity for the protective antigens F and HN, respectively.

88 Protective antigen facilitated the diffusion of LF and E

89 pleiotropic functions, it is not a dominant, protective antigen for antibody-mediated protection agai

90 examined whether this factor is a potential protective antigen for B. parapertussis.

91 eu5Ac is an essential virulence factor and a protective antigen for GBM, E. coli K1, and P. haemolyti

92 lethal factor, Certhrax was found to require protective antigen for host cell entry.

93 Since the O antigen is a protective antigen for many pathogenic bacteria, we exam

94 ependent surface feature and promising novel protective antigen for preventing P. aeruginosa infectio

95 scape from opsonophagocytic killing and as a protective antigen for S. aureus vaccines.

96 er membrane protein B (rOmpB), constitutes a protective antigen for this group of pathogens.

97 strains, we sought to determine if YopE is a protective antigen for Yersinia pseudotuberculosis and i

98 oteomic analysis as a point of discovery for protective antigens for possible inclusion in a vaccine

99 red for virulence and antigenic may serve as protective antigens for vaccination; thus, five represen

100 Protective antigen forms oligomeric prepores that underg

101 PA63 (the 63-kDa, C-terminal part of protective antigen) forms heptameric channels in cell me

102 ally important activities of its target, the protective antigen from Bacillus anthracis We show how r

103 protein microarray analyses; and (ii) known protective antigens from the literature.

104 oprotein, the viral neutralization and major protective antigen, from an added transcriptional unit.

105 spores with a deletion of the pBCXO1-carried protective antigen gene (pagA1) were severely attenuated

106 The primary cellular receptors for protective antigen have been identified and constructed

107 Presently, 590 protective antigens have been curated against over 100 i

108 While S. aureus protective antigens have been identified in the literatu

109 e is still no vaccine, even though potential protective antigens have been identified.

110 spores with a deletion of the pBC218-carried protective antigen homologue (pagA2) were not.

111 ly on homology with previously characterized protective antigens; however, homology-based methods wil

112 hough haemagglutinin plays a major role as a protective antigen, immunity to NA also contributes to p

113 ysaccharide (Ft LPS) is thought to be a main protective antigen in mice and humans, and we have previ

114 romotes influenza virus entry and is the key protective antigen in natural immunity and vaccines.

115 Animals with detectable protective antigen in serum, a significant increase in t

116 simultaneous detection of lethal factor and protective antigen in serum.

117 nt report demonstrates expression of anthrax protective antigen in tobacco chloroplasts--this materia

118 Filling a gap in the current knowledge of protective antigens in humans, our data support the key

119 D) and IpaB, have been identified as broadly protective antigens in the mouse lethal pneumonia model.

120 apparatus (T3SA) proteins IpaB and IpaD are protective antigens in the mouse lethal pulmonary model.

121 To appreciate the selection of protective antigens in this model, we sought to characte

122 Protective antigen is not only a vaccine component and t

123 Discovery of novel protective antigens is fundamental to the development of

124 Yet knowledge of protective antigens is limited.

125 To support data exchange, the information of protective antigens is stored in the Vaccine Ontology (V

126 We evaluated the ability of the protective antigen, LcrV, and a mutant derivative, V10,

127 The tripartite anthrax toxin consists of protective antigen, lethal factor (LF), and edema factor

128 ed in vitro assembly system, anthrax toxins, protective antigen, lethal factor and their domains, fus

129 ructural genes for the toxin proteins, i.e., protective antigen, lethal factor, and edema factor, dis

130 The Bacillus anthracis secretome includes protective antigen, lethal factor, and edema factor, whi

131 Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is

132 Immunoelectron microscopy with mAbs to protective antigen, lethal factor, edema toxin, and anth

133 ores formed in the endosomal membrane by the protective antigen moiety of anthrax toxin serve as port

134 ores formed in the endosomal membrane by the Protective Antigen moiety of anthrax toxin translocate t

135 hese are both binary-type toxins composed of protective antigen necessary for their cellular uptake a

136 The immobilization of a model ligand, the protective antigen of anthrax on the gold surface, is mo

137 faster immunoglobulin G response against the protective antigen of anthrax than AVA alone.

138 eered for stable plasmid-based expression of protective antigen of anthrax toxin (PA83) fused with th

139 Protective antigen of anthrax toxin forms a pore through

140 to form large pores in the membrane and the protective antigen of anthrax toxin, where a heptameric

141 ata suggest that the O antigen is a critical protective antigen of B. parapertussis and its inclusion

142 gment (scFvs) with increased affinity to the protective antigen of Bacillus anthracis were isolated f

143 ibodies with nanomolar affinities toward the protective antigen of Bacillus anthracis.

144 ot affect the expression of the gene for the protective antigen of the anthrax toxin, pagA, or that o

145 >8)-alpha-Neu5Ac is a virulence factor and a protective antigen of these three pathogens, it is also

146 ugh the detection of its polypeptide entity, protective antigen (PA toxin) using a PA toxin ssDNA apt

147 n only the protease-activated 63-kDa form of protective antigen (PA(63)) and the residual 20-kDa frag

148 y block the cation-selective channel-forming protective antigen (PA(63)) component of the binary anth

149 andwich pair for the detection of an anthrax protective antigen (PA(83)).

150 The action of anthrax toxin begins when the protective antigen (PA(83), 83 kDa) moiety binds to a ma

151 gle-chain variable fragments (scFvs) against protective antigen (PA) and 2 scFvs against lethal facto

152 Edema toxin, consisting of protective antigen (PA) and edema factor (EF), causes th

153 te anthrax lethal toxin (LeTx) consisting of protective antigen (PA) and lethal factor (LF) is a majo

154 n monoclonal antibodies with specificity for protective antigen (PA) and lethal factor (LF).

155 toxin (LT) is a bipartite toxin composed of protective antigen (PA) and lethal factor (LF).

156 and cell-mediated immune (CMI) responses to protective antigen (PA) and lethal factor were assayed b

157 s composed of the receptor-binding component protective antigen (PA) and of the adenylyl cyclase cata

158 ernatant of Bacillus anthracis, contains the protective antigen (PA) and traces of the lethal and ede

159 f three proteins: the translocase component, protective antigen (PA) and two enzyme components, letha

160 Atx is comprised of three proteins: protective antigen (PA) and two enzymes, lethal factor (

161 use a B-cell epitope from Bacillus anthracis protective antigen (PA) as a model antigen to characteri

162 a) 305 to 319 from the 2beta2-2beta3 loop of protective antigen (PA) can elicit high-titered antibody

163 cellular uptake of complexes containing the protective antigen (PA) carrier of anthrax toxin moietie

164 imals vaccinated with inactivated spores and protective antigen (PA) compared to vaccination with PA

165 acidic endosomal pH conditions, the toxin's protective antigen (PA) component forms a transmembrane

166 Proteolytic activation of the protective antigen (PA) component of anthrax toxin allow

167 The neutralizing antibody response to the protective antigen (PA) component of anthrax toxin elici

168 wn that Lactobacillus gasseri expressing the protective antigen (PA) component of anthrax toxin genet

169 The protective antigen (PA) component of the anthrax toxin (

170 The protective antigen (PA) component of the anthrax toxin f

171 The protective antigen (PA) component of the toxin assembles

172 The role of the protective antigen (PA) component of the toxin is to del

173 toxin is a tripartite toxin comprised of the protective antigen (PA) component, a homooligomeric tran

174 Anthrax toxin protective antigen (PA) delivers its effector proteins i

175 To detect low levels of the anthrax protective antigen (PA) exotoxin in biological fluids, w

176 Following assembly, the anthrax protective antigen (PA) forms an oligomeric translocon t

177 In this study, we modified the B. anthracis protective antigen (PA) gene for optimal expression and

178 Bacillus anthracis protective antigen (PA) is an 83-kDa (PA83) protein that

179 Protective antigen (PA) is essential for the action of B

180 man CMG2 receptor and the Bacillus anthracis protective antigen (PA) is essential for the transport o

181 Protective antigen (PA) is the anthrax toxin protein rec

182 Protective antigen (PA) is the cell surface recognition

183 The anthrax protective antigen (PA) is the receptor-binding subunit

184 The protective antigen (PA) moiety of anthrax toxin binds to

185 stry differed in sensitivity mediated by the protective antigen (PA) moiety of anthrax toxin by more

186 The protective antigen (PA) moiety of anthrax toxin forms a

187 The protective antigen (PA) moiety of anthrax toxin forms ol

188 toxin relies in part upon the ability of the protective antigen (PA) moiety to form a heptameric pore

189 pore in the endosomal membrane formed by the protective antigen (PA) moiety.

190 tation also promoted anti-Bacillus anthracis protective antigen (PA) neutralizing antibodies and enha

191 n of immune-enhancing cytokine IL-15 and the protective antigen (PA) of B. anthracis into the Wyeth v

192 Cellular immune responses against protective antigen (PA) of Bacillus anthracis in subject

193 ss II tetramers containing peptides from the protective antigen (PA) of Bacillus anthracis to detect

194 3' UTR, regulating expression of the anthrax protective antigen (PA) or human proinsulin (Pins) fused

195 toxin and edema toxin, which are composed of protective antigen (PA) plus either lethal factor (LF) o

196 plexes, each containing a heptameric form of protective antigen (PA) plus up to a total of three mole

197 the anthrax bacillus is to determine how the protective antigen (PA) pore mediates translocation of t

198 ion, when these MAbs were mixed with MAbs to protective antigen (PA) previously generated in our labo

199 subprotective dose of a neutralizing MAb to protective antigen (PA) prolonged mean time to death of

200 The protective antigen (PA) protein binds to receptors, eith

201 5 adenovirus (Ad) vector expressing anthrax protective antigen (PA) provides rapid protection agains

202 The absence of capsule or protective antigen (PA) resulted in complete avirulence,

203 tive, specific and easy detection of anthrax protective antigen (PA) toxin in picogram concentration

204 us acidophilus to deliver Bacillus anthracis protective antigen (PA) via specific dendritic cell-targ

205 Large polypeptides of the Bacillus anthracis protective antigen (PA) were inserted into an influenza

206 capsule and two binary toxins, complexes of protective antigen (PA) with lethal factor (LF) and edem

207 er a human monoclonal antibody (AVP-21D9) to protective antigen (PA) would protect mice, guinea pigs,

208 ancing or neutralizing to Bacillus anthracis protective antigen (PA), a component of anthrax toxin, r

209 Protective antigen (PA), a key component of anthrax toxi

210 is composed of a translocase channel, called protective antigen (PA), and an enzyme, called lethal fa

211 , consisting of the cellular binding moiety, protective antigen (PA), and the catalytic moiety, letha

212 translocase channel-forming subunit, called protective antigen (PA), and two substrate proteins, cal

213 ith AVP-21D9, a human monoclonal antibody to protective antigen (PA), at the time of Bacillus anthrac

214 The third, termed Protective Antigen (PA), is a multifunctional protein th

215 The toxin is composed of three proteins, protective antigen (PA), lethal factor (LF), and edema f

216 Anthrax toxin, comprising three proteins-protective antigen (PA), lethal factor (LF), and edema f

217 The anthrax toxins are three polypeptides-protective antigen (PA), lethal factor (LF), and edema f

218 gh degree of metabolic activity and secreted protective antigen (PA), lethal factor, and edema factor

219 plasmid pXO1 that encodes the toxin protein protective antigen (PA), lethal factor, and edema factor

220 x disease is caused by a toxin consisting of protective antigen (PA), lethal factor, and edema factor

221 lf-assembly of its three component proteins--protective antigen (PA), lethal factor, and edema factor

222 Protective antigen (PA), lethal factor, and edema factor

223 illus anthracis edema toxin (ET) consists of protective antigen (PA), necessary for host cell toxin u

224 The toxin's channel-forming component, protective antigen (PA), oligomerizes to create a precha

225 ate protein components: the receptor-binding protective antigen (PA), the adenylyl cyclase edema fact

226 Bacillus anthracis protective antigen (PA), the B subunit of the binary ant

227 Protective antigen (PA), the binding subunit of anthrax

228 and induces neutralizing antibodies against protective antigen (PA), the cell-binding component of a

229 iated vasculature and acts as a receptor for Protective Antigen (PA), the cell-binding component of t

230 ies to the immune system in combination with protective antigen (PA), the principal immunogen in AVA,

231 cillus anthracis vaccine consists largely of protective antigen (PA), the protein of anthrax toxin th

232 Protective antigen (PA), the receptor-binding component

233 bipartite toxin in which the first protein, protective antigen (PA), transports the second protein,

234 nto the host-cell cytosol by a third factor, protective antigen (PA), which binds to cellular anthrax

235 nto host cells through interactions with the protective antigen (PA), which binds to host cellular re

236 ty-enhanced monoclonal antibody (ETI-204) to protective antigen (PA), which is the central cell-bindi

237 Current evidence suggests that protective antigen (PA)-based anthrax vaccines may elici

238 genotypes, haplotypes, and homozygosity and protective antigen (PA)-specific cellular immune respons

239 rearrangement of sub-domains of the exotoxin protective antigen (PA).

240 segments derived from the Bacillus anthracis protective antigen (PA).

241 es the binding of the anthrax toxin subunit, protective antigen (PA).

242 the adenylate cyclase edema factor (EF) and protective antigen (PA).

243 edema factor (EF) to the pore-forming moiety protective antigen (PA).

244 thal toxin (LT), a complex of LF and anthrax protective antigen (PA).

245 factor (LF) enzymes, and the multifunctional protective antigen (PA).

246 rimary protective component is thought to be protective antigen (PA).

247 ethal factor (LFn), which were used with Atx protective antigen (PA).

248 Anthrax protective antigen (PA, 83 kDa), a pore-forming protein,

249 creted by fully virulent Bacillus anthracis, protective antigen (PA, 83 kDa), lethal factor (LF, 90 k

250 The wild-type protective antigen (PA-WT) of the binary anthrax lethal

251 cation pathway and found that binding of the protective-antigen (PA) component of LT to cells and the

252 hrax edema toxin (ET; edema factor [EF] plus protective antigen [PA]) and lethal toxin (LT; lethal fa

253 Single channels of Bacillus anthracis protective antigen, PA(63), were reconstituted into plan

254 into cancer cells using a toxin transporter (Protective antigen, PA) which was redirected to Epiderma

255 that bound and neutralized the pagA1-encoded protective antigen (PA1) but not the PA2 orthologue enco

256 plasmid that encodes the Bacillus anthracis protective antigen (PA63) gene fragment, it was shown th

257 We utilized full-length protective antigen (PA83) of anthrax toxin from Bacillus

258 tro against the fluorescent peptide, anthrax protective antigen (PA83), and influenza hemagglutinin s

259 lethal factor (lef), edema factor (cya), or protective antigen (pagA).

260 of this pathogen have made the discovery of protective antigens particularly difficult.

261 hem, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a

262 Protective antigens play important roles in vaccine deve

263 h direct electron counting, we determine the protective antigen pore structure at 2.9-A resolution.

264 e for CCT in translocation of LF through the protective antigen pore.

265 w that both variants can translocate through protective antigen pore.

266 Although atomic structures of protective antigen prepores are available, how protectiv

267 wcaM)8 mutation resulted in higher levels of protective antigen production during in vitro growth.

268 mid with lux expression under control of the protective antigen promoter displayed luminescence only

269 LcrV of Yersinia pestis is a major protective antigen proposed for inclusion in subunit pla

270 A mAb to protective antigen protected macrophages against vesicle

271 Using ovalbumin and Bacillus anthracis protective antigen protein as model antigens, we showed

272 his sandwich immunoassay, the model analyte, protective antigen protein from B. anthracis, was captur

273 Deletion of protective antigen resulted in greater loss of virulence

274 the expression of a major neutralization and protective antigen, resulting in reduced immunogenicity.

275 Immunization with a recombinant form of the protective antigen (rPA) from Bacillus anthracis has bee

276 mmunized with recombinant Bacillus anthracis protective antigen (rPA) mixed in NE as an adjuvant.

277 The recombinant protective antigen (rPA) of Bacillus anthracis is a prom

278 uginosa exotoxin A, recombinant B. anthracis protective antigen (rPA), and tetanus toxoid (TT).

279 ether spontaneous deamidation of recombinant protective antigen (rPA)--the major component of new-gen

280 ation interface is developed for interactive protective antigen search.

281 otective antigen prepores are available, how protective antigen senses low pH, converts to active por

282 he contribution of this network in evoking a protective antigen-specific immune response in the brain

283 ss of vaccine adjuvants, capable of inducing protective antigen-specific immune responses through nee

284 idence for a "loop swap" between neighboring protective antigen subunits, which is required for effic

285 a chimpanzee-derived monoclonal antibody to protective antigen that improved survival when administe

286 plague bacterium Yersinia pestis is a potent protective antigen that is under development as a vaccin

287 is of this immunity or the identification of protective antigens that enable vaccine development was

288 xpresses a variety of structurally conserved protective antigens that include cell surface polysaccha

289 This analysis identified protective antigens that, when tested as vaccines in mic

290 tus from structure-based studies of its main protective antigen, the fusion (F) glycoprotein.

291 creted by Bacillus anthracis, interacts with protective antigen to form a bipartite toxin (lethal tox

292 , the ability of rTP0136 protein to act as a protective antigen to subsequent challenge with infectio

293 e of glucose increased the expression of the protective antigen toxin component-encoding gene (pagA)

294 Hyperimmunization with anthrax protective antigen triggered a hIgG-mediated humoral imm

295 form of the CFA/I fimbrial tip adhesin, is a protective antigen, using a lethal neonatal mouse ETEC c

296 munoassay, a limit of detection of 4.1 ng/mL protective antigen was observed with an upper limit of 5

297 the hypothesis that deletion of gD-2 unmasks protective antigens, we evaluated the efficacy and safet

298 However, when several known protective antigens were deleted, the killed pneumococca

299 GENpro correctly classifies 82% of the known protective antigens when trained using only the protein

300 Bacillus anthracis infection is a complex of protective antigen, which localizes the toxin to the cel